The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation

Journal of Clinical Virology

Volumn 54, Issue 1, 2012, Pages 66-72

  Ji, Dong ^a   Liu, Yan ^a   Li, Le ^a   Xu, Zhihui ^a   Si, Lan Lan ^a   Dai, Jiu Zeng ^a   Li, Xiaodong ^a   Wang, Lin ^a   Yao, Zengtao ^a   Xin, Shao Jie ^a   Chen, Guo Feng ^a   Xu, Dongping ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

Drug resistance; Hepatitis b virus; Lamivudine; Mutation

Indexed keywords

LAMIVUDINE; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; CELL STRAIN HEPG2; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE; CHINA; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; VIRUS REPLICATION;

EID: 84862779361     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.02.003     Document Type: Article

References (29)

1. Lu F.M., Zhuang H. Management of hepatitis B in China. Chin Med J (Engl) 2009, 122:3-4.
2. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
3. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
4. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254-265.
5. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
6. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
7. Borroto-Esoda K., Miller M.D., Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007, 47:492-498.
8. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
9. Baldick C.J., Eggers B.J., Fang J., Levine S.M., Pokornowski K.A., Rose R.E., et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008, 48:895-902.
10. Delaney W.E., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77:11833-11841.
11. Ono S.K., Kato N., Shiratori Y., Kato J., Goto T., Schinazi R.F., et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001, 107:449-455.
12. Warner N., Locarnini S., Kuiper M., Bartholomeusz A., Ayres A., Yuen L., et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007, 51:2285-2292.
13. Inoue J., Ueno Y., Wakui Y., Niitsuma H., Fukushima K., Yamagiwa Y., et al. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepatitis 2011, 18:206-215.
14. Ciancio A., Smedile A., Rizzetto M., Lagget M., Gerin J., Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004, 39:64-73.
15. Kwon S.Y., Park Y.K., Ahn S.H., Cho E.S., Choe W.H., Lee C.H., et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010, 84:4494-4503.
16. Chinese Society of Infectious Diseases and Parasitology; Chinese Society of Hepatology Management scheme of diagnostic and therapy criteria of viral hepatitis. ZhonghuaGanZang Bing ZaZhi 2000, 8:324-329.
17. Liu Y., Wang C., Zhong Y., Chen L., Li X., Ji D., et al. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther 2010, 15:1185-1190.
18. Liu Y., Wang C., Zhong Y., Li X., Dai J., Ren X., et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analog(s)-experienced Chinese patients with chronic HBV infection. J Viral Hepatitis 2011, 18:e29-e39.
19. Liu Y., Zhong Y., Zou Z., Xu Z., Li B., Ren X., et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol 2010, 47:243-247.
20. Xu Z., Liu Y., Xu T., Chen L., Si L., Wang Y., et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol 2010, 48:270-274.
21. Ji D., Liu Y., Si L.L., Li L., Chen G.F., Xin S.J., et al. Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients. Clin Chim Acta 2011, 412:305-313.
22. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006, 26:171-180.
23. Gunther S., Li B.C., Miska S., Kruger D.H., Meisel H., Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995, 69:5437-5444.
24. Durantel D., Carrouee-Durantel S., Werle-Lapostolle B., Brunelle M.N., Pichoud C., Trepo C., et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004, 40:855-864.
25. Bhattacharya D., Thio C.L. Review of hepatitis B therapeutics. Clin Infect Dis 2011, 51:1201-1208.
26. Villet S., Pichoud C., Villeneuve J.P., Trepo C., Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006, 131:1253-1261.
27. Villet S., Billioud G., Pichoud C., Lucifora J., Hantz O., Sureau C., et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009, 136:168-176.
28. Torresi J., Earnest-Silveira L., Civitico G., Walters T.E., Lewin S.R., Fyfe J., et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the " fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002, 299:88-99.
29. Yang H., Westland C.E., Delaney W.E., Heathcote E.J., Ho V., Fry J., et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002, 36:464-473.